Tesamorelin: The Member That Finished the Trials

The short version

Tesamorelin, sold as Egrifta, is the one compound on this desk that cleared a regulator. It is a synthetic copy of growth-hormone-releasing hormone with a small chemical modification that stops a blood enzyme from breaking it down, and it works by prompting the pituitary to release more of the body's own growth hormone.

It was approved in the United States in 2010 for one specific job: reducing excess abdominal fat in people with HIV who developed lipodystrophy on antiretroviral therapy ^[13]. The fat it reduced in trials was the deep visceral fat around the organs, measured on scans rather than by weighing people, and it reduced liver fat as well ^[14].

Two further facts shape how the result should be read. The effect holds while the drug is taken and reverses when it stops ^[16]. And every other use discussed for it anywhere - general fat loss, anti-aging, cognition, non-HIV fatty liver - is off-label and is not what the trials tested.

What tesamorelin is

Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone, GHRH(1-44)-NH2, carrying a trans-3-hexenoic acid group conjugated to the N-terminus. That N-terminal modification is the whole engineering idea: it confers resistance to cleavage by dipeptidyl peptidase-IV, the enzyme that inactivates native GHRH within minutes, and so extends plasma stability enough to make a practical dosing schedule possible. The free base has the empirical formula C221H366N72O67S; the clinical product is supplied as the acetate salt and marketed as Egrifta.

Its regulatory position is unique within this hub. Tesamorelin holds an FDA approval - NDA 022505, granted November 2010 - to reduce excess abdominal fat in HIV-infected adults with lipodystrophy ^[13]. There is no approved indication outside that population anywhere in the world.

It remains prohibited in sport under WADA category S2 as a GHRH analogue, in and out of competition. And research-grade tesamorelin supplied for laboratory use is a different article from the approved product: it carries none of the purity and potency oversight that the prescription medicine does, which is worth keeping in view whenever a study result for the approved drug is cited in a non-prescription context.

How it works

Tesamorelin binds the growth-hormone-releasing-hormone receptor on anterior-pituitary somatotrophs and activates the Gs / adenylyl-cyclase / cyclic-AMP / protein-kinase-A cascade, stimulating synthesis and pulsatile secretion of endogenous growth hormone. That growth hormone drives hepatic production of IGF-1, and together the two promote lipolysis preferentially in visceral adipose tissue rather than in subcutaneous fat - which is why the trials measured a cross-sectional area on a scan rather than a number on a scale.

The word pulsatile is the part that distinguishes tesamorelin from injecting growth hormone itself. Because it amplifies the body's own rhythm rather than supplying a flat exogenous level, its metabolic profile differs from recombinant growth hormone's, and the human data bear that out.

In thirteen healthy men given 2 mg per day for two weeks, mean overnight growth hormone rose by 0.5 micrograms per liter (P=0.004) and IGF-1 rose by 181 micrograms per liter (P<0.0001), while fasting glucose was unchanged (P=0.93) and insulin-stimulated glucose uptake was unchanged (P=0.61) ^[15]. A compound that moves the growth-hormone axis that clearly without measurably degrading insulin sensitivity over that window is doing something that exogenous growth hormone generally does not.

What the trials measured

The pooled result. A 2026 meta-analysis of five randomized controlled trials in HIV-associated lipodystrophy found tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), trunk fat by -1.18 kg and hepatic fat fraction by -4.28%, while increasing lean body mass by +1.42 kg - all at P<0.001, and without serious adverse events ^[8].

The imaging trial. A six-month randomized controlled trial published in JAMA enrolled 50 antiretroviral-treated adults with HIV, 28 on tesamorelin and 22 on placebo, at 2 mg per day. The treatment effect on visceral fat was -42 cm2 (P=0.005), and hepatic lipid-to-water percentage fell by a net -2.9% (P=0.003) ^[14]. Two endpoints, two measurement modalities, one six-month window: this is the design that makes the visceral- and hepatic-fat claims specific rather than general.

The long trial. The 52-week program randomized 273 participants to tesamorelin 2 mg per day against 137 on placebo. Visceral adipose tissue reduction was sustained at -18% over 52 weeks (P<0.001 versus baseline). Two findings from that program matter as much as the efficacy number: visceral fat reaccumulated upon discontinuation, and changes in glucose parameters across the full 52 weeks were not clinically significant ^[16].

The mechanistic human study. The two-week study in thirteen healthy men described above ^[15] is the one place in this hub where the growth-hormone and IGF-1 response to a GHRH analogue was measured directly in people alongside a glucose endpoint, rather than inferred from a receptor model.

Liver safety. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E - unlikely cause of clinically apparent liver injury - noting no reported attributable liver-injury cases and no de novo serum-enzyme elevations in trials ^[13].

Read together, that is a coherent applied program: a mechanism study establishing the hormonal response, a six-month trial establishing the imaging endpoints, a 52-week trial establishing durability, reversibility and metabolic safety, and a meta-analysis pooling the set. Nothing else on this axis has an equivalent.

Safety, tolerability and the limits of the label

Tesamorelin is the one member of this hub whose safety profile comes from randomized trials rather than from community report, and within the population studied that profile is comparatively reassuring: no serious adverse events in the pooled analysis ^[8], no clinically significant glucose change across 52 weeks ^[16], no measurable effect on insulin-stimulated glucose uptake over two weeks in healthy men ^[15], and a LiverTox likelihood score of E for liver injury ^[13].

The limits are just as well documented, and most of them are limits of scope rather than of tolerability.

The approval covers HIV-associated lipodystrophy and nothing else. General visceral-fat reduction, anti-aging use, cognitive enhancement and non-HIV fatty liver disease are all off-label and investigational. The pivotal trials enrolled HIV-positive adults on antiretroviral therapy, so extending the result to other populations is mechanistically plausible but not established by large randomized trials.

The benefit is contingent on continued administration: visceral fat reaccumulates within weeks of discontinuation ^[16].

Because the compound works by raising growth hormone, it raises serum IGF-1, a growth factor. Trials showed no excess malignancy signal over 52 weeks, but long-term oncologic-safety data are limited and active malignancy is a labeled contraindication.

Modest glucose perturbation can occur, and monitoring is the standard caution in anyone with prediabetes or dysglycemia, even though the dedicated type-2-diabetes trial found no significant change in HbA1c.

Cognitive findings are mixed rather than positive. A non-HIV aging trial showed an executive-function benefit, while a 2025 HIV cognition trial did not show significant neurocognitive improvement over standard care - a useful reminder that a positive result in one population is a hypothesis in another.

Finally there is an access reality with a safety consequence: high pharmaceutical cost and injection-only administration push people toward research-grade material that lacks the purity and potency oversight of the approved product, which is a different article from the one that produced every number on this page.

Where it sits on the growth-hormone axis

Tesamorelin is the control condition for this whole hub. It is the same class of intervention as the other two members - stimulate endogenous growth hormone rather than replace it - carried through the full applied sequence: a defined population, imaging endpoints, a 52-week randomized trial, a documented discontinuation effect, a metabolic safety readout and a published meta-analysis.

That is what makes it the useful comparator rather than the headline. When a claim is made for any GHRH analogue on this axis, tesamorelin is the compound where an equivalent claim has actually been tested, and the honest question to put to any other member is whether an equivalent study exists. For ipamorelin, one Phase 2 trial exists and it missed its primary endpoint ^[3]. For the CJC-1295 pairing, none exists at all.

It is worth noting what tesamorelin's file does not contain: there is no community-report literature of the kind that surrounds the unapproved members, because people obtaining a prescription medicine are documented in pharmacovigilance rather than in forums. The absence of anecdote here is a feature of how the compound is supplied, not a property of the molecule.